miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR

HCC is a common malignancy worldwide and surgery or reginal treatments are deemed insufficient for advanced-stage disease. Sorafenib is an inhibitor of many kinases and was shown to benefit advanced HCC patients. However, resistance emerges soon after initial treatment, limiting the clinical benefit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Ji, Lin, Lin, Zhongjie, Wan, Zhe, Xia, Shunjie, Jiang, Shi, Cen, Dong, Cai, Liuxin, Xu, Junjie, Cai, Xiujun
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170966/
https://ncbi.nlm.nih.gov/pubmed/32313144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2413-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados